Recent Updates
Recently added Catalysts
AZN Positive Sentiment

AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib

Monday, October 19, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: AstraZeneca is set to present significant overall survival data from four pivotal Phase III trials at the ESMO Congress scheduled for October 23-27, 2026. This presentation will include findings from its leading cancer therapies, including Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib), and savolitinib. The data aims to highlight AstraZeneca's commitment to advancing cancer treatment.

Market Sentiment Analysis

POSITIVE FACTORS

  • AstraZeneca is showcasing new data to revolutionize cancer care.
  • Presentation includes results from five pivotal Phase III trials.
  • The company is leading with innovative treatments in oncology.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+8%
120-day peak, hindsight
Typical move
1.5%
average across 15 past catalysts
Lead asset
Elecoglipron
Phase 3 · Chronic Kidney Disease

Full Press Release Details

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to revolutionize cancer care with new data across its diverse, industry-leading portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, October 23-27, 2026. More than 100 abstracts will be presented, including data from five pivotal Phase III trials, four of which will be featured in Presidential Symposia. This breadth of data will demonstrate how AstraZeneca is redefining the way cancer is treated

Frequently Asked Questions

What will AstraZeneca present at ESMO 2026?

AstraZeneca will present overall survival data from four pivotal Phase III trials.

When is the ESMO Congress taking place?

The ESMO Congress is scheduled for October 23-27, 2026.

Which therapies are included in the presentations?

The presentations will feature Sone-Ve, IMFINZI®, TAGRISSO®, and savolitinib.

How many abstracts will AstraZeneca present?

AstraZeneca will present more than 100 abstracts at the congress.

ShareAdd on Google
Tags: AZN AstraZeneca ESMO 2026 Phase III trials cancer treatment IMFINZI
Last updated: Oct 19, 2026

Biotech snapshot

Lead asset
ElecoglipronPhase 3
Chronic Kidney Disease →

Catalyst track record

+8%
best trade around AZN's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for AZN.

See every catalyst's timing & PoA →